en · de · es · fr · pt
faq-desk.peptides7250.com › News › Compound Identity And Development History — Practical Notes

Compound Identity And Development History — Practical Notes

By Editorial Desk · published 2025-10-01 · last reviewed 2025-10-27 · News

Everything below concerns reverse-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Updated 2025-10-27. Numbers and descriptions here follow the published literature rather than marketing material.

Compound Identity and Development History

Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.

CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.

Persistence, Stability and Measurement

Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.

The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.

Cjc-1295 at a glance

PropertyValueNotes
Molecular formulaC152H252N44O42Cited for the form without the drug affinity complex
Molecular weightAbout 3368 DaReported value for modified GRF(1-29)
AppearanceWhite to off-white powderLyophilised solid as usually supplied
SolubilitySoluble in water and polar solventsClarity depends on purity and salt content
Typical storage-20 C or below, dryProtect from light and repeated warming cycles

Background and Molecular Features

The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.

CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.

Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.

Related pages on this site

Handling Storage and Quality Control

Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.

Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.

Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.

CJC-1295 Background and Mechanism

The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.

Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.

CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.

Reference notes

Tetrahydrobiopterin (branded as Kuvan) (sapropterin dihydrochloride), a small molecule drug for phenylketonuria, introduced in 2007 as the first medication-based intervention to treat phenylketonuria Arylsulfatase B (branded as Naglazyme) (galsulfase), a recombinant protein therapeutic for Maroteaux–Lamy syndrome (also called mucopolysaccharidosis type VI) Iduronidase (branded as Aldurazyme), a recombinant protein therapeutic for mucopolysaccharidosis I Amifampridine (branded as Firdapse), a small molecule drug for Lambert–Eaton myasthenic syndrome (as of 2013 approved in the EU only) Elosulfase alfa (branded as Vimizim), is the only enzyme replacement therapy to address the cause of Morquio A Syndrome (MPS IVA), which affects an estimated 3,000 patients in the developed world. The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan (GAG) metabolism. Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017. Valoctocogene roxaparvovec (branded as Roctavian) is an adeno-associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one. It was approved in the EU in August 2022. Biomarin is working to develop several new drugs.

=== Side effects === Side effects of alcohol and beta blockers include high blood pressure, dizziness, nausea, diarrhea, constipation, slow heartbeat, liver disease, cancer, dementia, and/or impotence or loss of sexual drive.

== Early career == Stansbury began her career as an ecology instructor at the New Mexico Museum of Natural History and Science. As a White House Fellow, she worked as a policy advisor on the Council on Environmental Quality. She was a consultant at Sandia National Laboratories and later served as a program examiner in the Office of Management and Budget during the Obama administration. She worked on the staff of the United States Senate Committee on Energy and Natural Resources and as an aide to Senator Maria Cantwell. Since 2017, she has worked as a consultant and senior advisor at the Utton Transboundary Resources Center of the University of New Mexico.

D. melanogaster males exhibit a strong reproductive learning curve. That is, with sexual experience, these flies tend to modify their future mating behavior in multiple ways. These changes include increased selectivity for courting only intraspecifically, as well as decreased courtship times. Sexually naïve D. melanogaster males are known to spend significant time courting interspecifically, such as with D. simulans flies. Naïve D. melanogaster will also attempt to court females that are not yet sexually mature, and other males. D. melanogaster males show little to no preference for D. melanogaster females over females of other species or even other male flies. However, after D. simulans or other flies incapable of copulation have rejected the males' advances, D. melanogaster males are much less likely to spend time courting nonspecifically in the future. This apparent learned behavior modification seems to be evolutionarily significant, because it allows the males to avoid investing energy into futile sexual encounters. In addition, males with previous sexual experience modify their courtship dance when attempting to mate with new females—the experienced males spend less time courting, so have lower mating latencies, meaning that they are able to reproduce more quickly. This decreased mating latency leads to a greater mating efficiency for experienced males over naïve males. This modification also appears to have obvious evolutionary advantages, because increased mating efficiency is extremely important in the eyes of natural selection.

===== Impact on impoverished communities ===== In countries where cocaine is illicitly produced, an intermediate product known as cocaine paste—often referred to as "poor man's cocaine"—is frequently smoked in impoverished communities. This substance is favored in these areas primarily because it is inexpensive and more accessible than refined cocaine. However, the use of cocaine paste poses severe health risks. During its production, various toxic chemicals are used to extract coca alkaloids from the coca leaves. Many of these hazardous substances, such as solvents and acids, remain in the paste after processing. When the paste is smoked, individuals are exposed not only to the addictive effects of the drug itself but also to the dangerous residual chemicals, which can cause significant harm to the lungs, nervous system, and overall health. This combination of affordability, accessibility, and toxicity makes cocaine paste particularly damaging to vulnerable populations in cocaine-producing regions.

Sources: en.wikipedia.org

Notes from published material

Vesugen (T-38) is a tripeptide with the sequence KED or Lys-Glu-Asp. It is one of a number of small peptides developed in Russia in the late 1990s and early 2000s which are purported to have anti-aging effects. Vesugen is claimed to stimulate proliferation and protein synthesis in fibroblast cells in the skin and to improve the appearance of skin, as well as promoting neurotropic effects in brain tissue, giving it a similar pharmacological profile to those claimed for the matrikine peptides produced by Western cosmetic skincare companies.

==== Addiction ==== Whether caffeine can result in an addictive disorder depends on how addiction is defined. Compulsive caffeine consumption under any circumstances has not been observed, and caffeine is therefore not generally considered addictive. Some diagnostic sources, such as the ICD-9 and ICD-10, include a classification of caffeine addiction under a broader diagnostic model. Caffeine does not appear to be a reinforcing stimulus, and some degree of aversion may actually occur, with people preferring placebo over caffeine in a study on drug abuse liability published in an NIDA research monograph. Some state that research does not provide support for an underlying biochemical mechanism for caffeine addiction. Other research states it can affect the reward system. "Caffeine addiction" was added to the ICD-9 and ICD-10. However, its addition was contested with claims that this diagnostic model of caffeine addiction is not supported by evidence. The American Psychiatric Association's DSM-5 does not include the diagnosis of a caffeine addiction but proposes criteria for the disorder for more study. As of 2021, the World Health Organization does not classify caffeine as an addictive substance.

== Further reading == C1q: structure, function, and receptors. Kishore U1, Reid KB. Immunopharmacology. 2000 Aug;49(1-2):159-70. Functional Complement C1q Abnormality Leads to Impaired Immune Complexes and Apoptotic Cell Clearance. Deciphering the fine details of C1 assembly and activation mechanisms: "mission impossible"? - detailed diagrams

=== Kidney disease === Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis that may be the initial manifestation of the disease. Renal vascular injury (due in part to collagen deposition) leads to renal ischemia, which results in activation of the renin-angiotensin-aldosterone system (RAAS). This raises blood pressure and further damages the renal vasculature, causing a vicious cycle of worsening hypertension and renal dysfunction (e.g., elevated creatinine, edema). Hypertensive emergency with end-organ dysfunction (e.g., encephalopathy, retinal hemorrhage) is common. Thrombocytopenia and microangiopathic hemolytic anemia can be seen. Urinalysis is usually normal but may show mild proteinuria, as in this patient; casts are unexpected. The mainstay of therapy for SRC includes ACE inhibitors, which reduce RAAS activity and improve renal function and blood pressure. Short-acting ACE inhibitors (typically captopril) are used because they can be rapidly uptitrated. An elevated serum creatinine level is not a contraindication for ACE inhibitors in this population, and slight elevations in creatinine are common during drug initiation. Scleroderma renal crisis, the occurrence of acute kidney injury, and malignant hypertension (very high blood pressure with evidence of organ damage) in people with scleroderma are effectively treated with drugs from the class of the ACE inhibitors.

Hasegawa, Shuichi; Levin, Christoph; Radner, Karen, eds. (2018). The Last Days of the Kingdom of Israel. Walter de Gruyter GmbH & Co KG. ISBN 978-3-11-056660-4. Joffe, Alexander H. (2002). "The Rise of Secondary States in the Iron Age Levant". Journal of the Economic and Social History of the Orient. 45 (4): 425–467. doi:10.1163/156852002320939311. JSTOR 3632872. McNutt, Paula (1999). Reconstructing the Society of Ancient Israel. Westminster John Knox Press. ISBN 978-0-664-22265-9. Archived from the original on 1 July 2023. Retrieved 14 August 2015. Manzur, Ibn (1979). "SMR". Lisan al Arab. Vol. 21. Al-dar al-Misriya li-l-talif wa-l-taryamar. ISBN 978-0-866-85541-9. Mendels, D. (1987). The Land of Israel as a Political Concept in Hasmonean Literature: Recourse to History in Second Century B.C. Claims to the Holy Land. Texte und Studien zum antiken Judentum. J.C.B. Mohr. ISBN 978-3-16-145147-8. Retrieved 7 December 2020. Na'aman, Nadav (2011). "The Exodus Story: Between Historical Memory and Historiographical Composition". Journal of Ancient Near Eastern Religions. 11: 39–69. doi:10.1163/156921211X579579. Redmount, Carol A. (2001) [1998]. "Bitter Lives: Israel in and out of Egypt". In Coogan, Michael D. (ed.). The Oxford History of the Biblical World. Oxford and New York: Oxford University Press. pp. 58–89. ISBN 978-0-19-513937-2. Archived from the original on 3 April 2023. Retrieved 26 June 2023. Tetley, M. Christine (2005). The Reconstructed Chronology of the Divided Kingdom. Eisenbrauns. pp. 105–. ISBN 978-1-57506-072-9. Tubb, Jonathan N. (1998). Canaanites.

Sources: en.wikipedia.org

Background from the literature

=== Algeria === Algeria is an oil and natural gas producer, and one of the European Union's largest suppliers of LNG. It has entered talks with Spain and Italy, as well as fielding enquiries from other countries, including Vietnam. It could benefit economically.

=== The New York Times === On April 2, 2023, the main account for The New York Times became one of the first major media companies to lose its verified status on Twitter. Ahead of the official release of Verification for Organizations, newspaper The New York Times stated that it would not pay for a verification checkmark. In response to a Twitter user who pointed out the newspaper's decision, Musk stated, "Oh ok, we'll take it off then". Musk then called The New York Times hypocritical for charging readers to read its articles. He criticised the newspaper for tweeting hundreds of posts every day, including drafts that were not accepted into the published editions of the paper, and inundating the daily feed of users who followed it. Despite the deadline for Twitter Blue passing, and aside from The New York Times, many legacy verified accounts continued to retain their verified status. According to The New York Times themselves, the top 10,000 Twitter accounts and top 500 advertisers would be exempt from paying.

There are three types of myomeres observed in fish-like chordates: amphioxine (lancelet), cyclostomine (jawless fish), and gnathostomine (jawed fish). All myomeres flex the body laterally into concavity to provide force for locomotion. Since myomeres are composed of multinucleated myofibers (contractile cells), force can be generated via muscle contraction that gets transmitted by the intricate connective tissue (myosepta) network. Myomeres compose most of the lateral musculature and provide propulsive force to travel along the line of travel. In this sense, they cause flexion to either side in order to produce locomotor force (the forward swimming motion). Myomeres attach to centra of vertebrae, and neural and haemal spines. The folded shape of each myomere as V- or W-shaped extends over various axial segments, allowing fibers control over a large amount of the body. There are different variations of myomere activation depending on the type of swimming or movement. For example, high loading situations such as fast-starts and turning require almost maximal myomere activation in teleost fish. Further, if swim speeds are lower and movement is in one plane, there is less activation of myomeres. Research has discovered that fish are able to spatially restrict axial myomeres during different swimming behaviors.

=== Cognitive symptoms === An obsession with counting calories and monitoring contents of food Preoccupation with food, recipes, or cooking; may cook elaborate dinners for others, but not eat the food themselves or consume a very small portion; can do so in order to distract others from noticing the condition Admiration of thinner people Thoughts of being fat or not thin enough An altered mental representation of one's body Impaired theory of mind, exacerbated by lower BMI and depression Memory impairment Difficulty in abstract thinking and problem solving Rigid and inflexible thinking Poor self-esteem Hypercriticism and perfectionism

The first history of Christian Science appeared in McClure's magazine in 14 installments from January 1907 to June 1908, preceded by an editorial in December 1906. The essence of the articles, which included court documents and affidavits from Eddy's associates, was that Eddy's chief concern was money, and that she had derived Christian Science from Quimby. The material was also published as a book, The Life of Mary Baker G. Eddy and the History of Christian Science (1909). It became the key source for most non-church histories of the religion. The editor-in-chief assigned five writers to work on the series, including the novelist Willa Cather as the principal author. The book was kept out of print from early in its life by the Christian Science church, which bought the original manuscript. It was republished in 1971 by Baker Book House when its copyright expired, and again in 1993 by the University of Nebraska Press.

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.

Is CJC-1295 an approved medicine?

No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.

How does it differ from sermorelin?

Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.

What is the difference between the forms with and without a drug affinity complex?

The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.

Network